Trial Profile
First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Anthrax vaccine (Primary) ; Anthrax vaccine
- Indications Anthrax
- Focus Adverse reactions; First in man
- Sponsors Altimmune
- 01 Apr 2019 According to an Altimmune media release, given the compelling nonclinical data obtained previously in two well-established animal models for anthrax, the Company is investigating all potential causes that may have contributed to the disparate results. Results of these investigations are expected in the first half of 2019.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2018 According to an Altimmune media release, the company will assay clinical samples from this phase I trial for mucosal immune response and compare different methods of administration in preclinical models.